Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.42 EUR | -0.98% | +2.18% | -1.42% |
Apr. 26 | FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Gets a Sell rating from Jefferies | ZD |
Apr. 24 | European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.42% | 11.72B | A- | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-3.97% | 11.66B | A- | ||
-31.75% | 11.77B | - | - | |
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG